Researchers have documented the safety profile observed in published Phase 2 research as predominantly gastrointestinal effects (nausea, diarrhoea, vomiting) typical of the incretin class, occurring most prominently during dose escalation and tending to decline with continued exposure (PMID 39515565, PMID 41785010)
Conclusion Flupirtine, an indirect NMDA receptor antagonist due to Kv7 channel activation and GABA A receptor agonism, is a novel analgesic medication with utility in the treatment of patients with fibromyalgia who have often proven refractory to standard anti-neuropathic pain medications
Additionally, it can reduce the risk of major adverse cardiovascular events in patients with pre-existing cardiovascular disease
Kaushal V, Klim J, Skoneczna A, Kurlandzka A, Enkhbaatar T, Kaczanowski S, et al